BioSpace News Archive

During the second quarter, NRx reactivated the development of NRX-101 and intends to initiate a Phase IIb/III study for ASIB by the end of this year or early 2023.

In a recently published study, researchers found that the link between the SOD1 protein and Amyotrophic Lateral Sclerosis (ALS) could extend to all types of the motor neuron disease.

As the biotech world awaits the announcement of Merck’s anticipated buyout of Seagen, an arbitrator came down on the side of Daiichi Sankyo in a patent battle against the Seattle-based biotech.

To help you in your job search, here are just a few of the remote job options in the life science industry, along with the qualifications and skills necessary to be successful in each role.

Novartis released results from the Phase III CANOPY-A trial, showing that its canakinumab candidate failed to meet its primary efficacy endpoint in adult NSCLC patients.

The U.K’s MHRA has granted conditional authorization to Moderna’s newest vaccine candidate, making it the first Omicron-specific COVID-19 booster vaccine approved by a regulatory agency.

After more than two decades of attempts to develop a universal influenza vaccine, the global COVID-19 pandemic intensified the need for a broader vaccine for both illnesses.

Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, provided a business update and reported financial results for the quarter ended June 30, 2022.

BD and Accelerate Diagnostics, Inc. announced a worldwide commercial collaboration agreement where BD will offer Accelerate’s rapid testing solution for antibiotic resistance and susceptibility offering results in hours, versus one to two days with some traditional laboratory methods.

Protalix BioTherapeutics, Inc. reported financial results for the second quarter ended June 30, 2022 and provided a business update on recent corporate and regulatory developments.